Skadden

September 2021



Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates

The Americas

Boston Chicago Houston Los Angeles New York Palo Alto São Paulo Toronto Washington, D.C Wilmington

Europe

russels rankfurt ondon loscow lunich aris

Asia Pacific

Beijing Hong Kong Seoul Shanghai Singapore Tokvo



With ongoing regulatory developments affecting capital markets globally, many China-related businesses are considering pursuing their IPOs in Hong Kong. However, the regulatory regime for IPOs on the Stock Exchange of Hong Kong Limited (HKEx) has a number of unique features and can pose unforeseen challenges for companies that may be familiar with or that have already commenced the IPO process in other markets. Accordingly, companies considering an IPO in Hong Kong need to be fully informed of the relevant HKEx requirements to be properly prepared and ensure a smooth IPO process.

This summary provides a high-level overview of the key issues for companies preparing to pursue an IPO in Hong Kong and seeking a primary listing on HKEx, with a particular focus on those features that may be distinctive from the requirements in other IPO markets.

This information is intended solely as a summary overview and is not intended to take the place of detailed legal advice based on the specific facts and circumstances in a particular case. We have assumed for the purposes of this summary that the company seeking listing is incorporated in the Cayman Islands. All references to rules refer to The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the Listing Rules). Separately, detailed requirements apply to companies with dual class share structures and pre-revenue biotech companies, which are beyond the scope of this document. This document also does not address the requirements for a secondary listing on HKEx.

One Manhattan West / New York, NY 10001 / 212.735.3000

42/F, Edinburgh Tower, The Landmark / 15 Queen's Road Central, Hong Kong / 852.3740.4700





- 1. Confirm Eligibility for Listing
- 2. Confirm the Accounting Standards and Trading Record
- **3. Confirm Management Continuity**
- 4. Confirm Ownership Continuity and Control
- 5. Engage Sponsor(s) Licensed To Conduct a HK IPO
- 6. Update Due Diligence
- 7. Verify the Prospectus
- 8. Confirm the Relationship With Controlling Shareholders
- 9. Check VIE Compliance
- **10. Review Pre-IPO Investment Agreements**
- 11. Disclose Mergers and Acquisitions
- 12. Consider Pre-A1 Submissions/Identify Key Waivers
- **13. Analyze Connected Transactions**

- 14. Appoint Various Intermediaries
- 15. Appoint Independent Nonexecutive Directors (INEDs)
- 16. Establish Board Committees
- **17.** Check Articles of Association Compliance
- **18. File Disclosure of Interests in Securities**
- 19. Check Option Schemes Compliance
- 20. Register Trademark
- **21. Register as Non-Hong Kong Company**
- 22. Prepare HK Prospectus
- 23. Prepare A1 Documents and A1 Redacted Proof Prospectus
- 24. Consider Weighted Voting Rights (WVR)/Dual Class Shares
- **25.** Considerations for Biotech Companies

lssue/Task	HKEx Requirement	Comment/Timing
1 Confirm Eligibility for Listing	 A company must have: Profit attributable to shareholders (excluding extraordinary items) of not less than HK\$20 million for the most recent year and not less than HK\$30 million in the two preceding fiscal years (in aggregate); OR HK\$2 billion market capitalization; HK\$500 million revenue in the previous fiscal year; and HK\$100 million cash flow in aggregate for the three most recent fiscal years; OR HK\$4 billion market capitalization; HK\$500 million revenue in the previous fiscal year. 	 For listing applications submitted on or after 1 January 2022, the profit requirement under the first test will be increased to HK\$35 million for the most recent year and not less than HK\$45 million in the two preceding fiscal years (in aggregate).
2 Confirm the Accounting Standards and Trading Record	 Audited accounts should adopt International Financial Reporting Standards or Hong Kong Financial Reporting Standards. A company needs a trading record of three years (unless listing under the market capitalisation/ revenue test, in which case the HKEx may accept a shorter trading record). 	 US generally accepted accounting principles (GAAP) and Public Company Accounting Oversight Board standards are not currently acceptable for a primary listing on the HKEx unless a dual primary listing of a U.Slisted company is occurring.
3 Confirm Management Continuity	 The majority of the board of directors and senior management should remain unchanged for the three preceding fiscal years. 	 The company/advisers should review any director-ship changes and changes in the senior management team prior to A1 filing to ensure continuity has been maintained.
4 Confirm Ownership Continuity and Control	 There should be no change in the company's controlling shareholders (defined as shareholders controlling 30% or more of the company, or, if no controlling shareholders, then largest share- holder) for the most recent full fiscal year. 	 The company/advisers should review any shareholding changes prior to A1 filing to ensure continuity has been maintained.
5 Engage Sponsor(s) Licensed To Conduct a HK IPO	 Appointment of Hong Kong-licensed sponsor(s) is required. At least one sponsor needs to be independent of the company. 	 The company must submit a copy of the duly signed sponsors' engagement letter to the HKEx at least two months before filing its A1. If any new sponsors are engaged after the initial submission of the sponsors' engagement letter to the HKEx, the company must wait for another two months to file its A1.
6 Update Due Diligence	 HKEx and the Securities and Futures Commission (SFC) impose detailed due diligence requirements on sponsors, as set out in Practice Note 21 of the Listing Rules. 	 Sponsors will likely be required to perform/ refresh certain due diligence steps and undertake third-party interviews (with suppliers, customers, finance providers and other third parties). The SFC requires that sponsors directly arrange these interviews and conduct them face-to-face.

lssue/Task	HKEx Requirement	Comment/Timing
7 Verify the Prospectus	 Under Hong Kong market practice, spon- sors' counsel undertakes verification of the prospectus content to ensure its accuracy. This process is separate from due diligence. 	 Sponsors' counsel must complete verification of the prospectus content before the company files its A1.
8 Confirm the Relationship With Controlling Shareholders	 HKEx requires listing applicants to demonstrate independence from their controlling shareholders in three key areas: management independence, operational independence and financial independence. There should be a clear delineation of business between the company and its controlling shareholders operate any businesses that may compete with the listing applicant, the company should establish that these are not material, and/or enter into appropriate noncompete agreements. 	 The company needs to: Ensure that no undue overlap of executive directors/senior management occurs between the company and the controlling shareholders. Ensure that the company does not rely on the controlling shareholder as a key supplier or customer or for other aspects essential to the operations of the business (<i>e.g.</i>, provision of technology/intellectual property, land, facilities, etc.). Ensure that no outstanding financial assistance (<i>e.g.</i>, loan or guarantee) exists between the company and the controlling shareholders at the time of listing. The company should therefore plan ahead to have these repaid/released no later than the time of listing.
9 Check VIE Compliance	 HKEx requires any VIE structures to be "narrowly tailored" so that only businesses in sectors prohibited/restricted from foreign investment are included in the VIE structure. Further requirements apply to the specific terms of VIE contracts. 	 In advance of A1 filing, PRC counsels will need to assess whether all businesses currently within the VIE structure are subject to foreign investment restrictions and that the terms of the VIE contracts comply with HKEx requirements. If not, restructuring the VIEs may be necessary in order to comply with the Listing Rules/guidance.
10 Review Pre-IPO Investment Agreements	 The company needs to complete and fully settle consideration of pre-IPO investments (including any transfer of shares) 28 clear days before A1 filing. The company must terminate almost all special rights given to pre-IPO investors upon listing. Guidance letters also prescribe detailed disclosure requirements for pre-IPO investments. These rules also apply to convertible shares/ instruments/loans. 	 Review the terms of all pre-IPO investments in advance of A1 filing to determine if they are in compliance with the guidance issued by the HKEx. If not, the company should start liaising with the pre-IPO investors to amend the agreements and ensure that any amendments are finalized prior to A1 filing. The company should also notify pre-IPO inves- tors to ensure they do not transfer their shares within 28 days prior to the expected date of A1 submission.

lssue/Task	HKEx Requirement	Comment/Timing
11 Disclose Mergers and Acquisitions	 If the size of any acquisitions within the three-year track record period is 25% or more (relative to the size of the company, as measured by revenues, total assets, profits and equity capital), the company will need to disclose separate accounts for these acquisition targets in the prospectus. If any acquisitions take place after the track record period, accounts of the target company must be disclosed regardless of the size test or any requested waiver from disclosure. 	 The company should identify any acquisitions made during the track record period with size tests of 25% or above and liaise with its auditors to assess the time required for them to prepare the relevant accounts to be disclosed in the prospectus. The company should assess whether any acquisitions are planned after the track record period and consider the implications for a Hong Kong IPO — deferring consideration of acquisitions to after the IPO may be advisable.
12 Consider Pre-A1 Submissions/ Identify Key Waivers	 HKEx allows Pre-A1 submissions on novel issues or key suitability issues. The Listing Rules are complex, but certain routine waivers can be granted. 	 The company and its advisers should consider whether the company is not able to comply with any HKEx requirements, either as to listing eligibility or general compliance, and if so, whether waivers might be sought. HKEx is open to meetings/communications with companies prior to A1 filing. Novel issues can be resolved by way of written Pre-A1 submissions.
13 Analyze Connected Transactions	 Connected transactions are subject to complex Listing Rules requirements. Generally, "connected transaction" refers to any transaction between the company (or its subsidiaries) and any "connected person" of the company (which includes directors, CEOs or holders of 10% or more voting rights of the company or its subsidiaries and their respective associates). Subject to certain exemptions, connected transactions require independent shareholders' approval. The company must also appoint an independent board committee and independent financial advisor who must confirm that the terms of the connected transaction are fair and reasonable. De minimis transactions below certain thresh- olds (measured against the company's profits, revenues, asset and market capitalization) are exempted from the requirements above. 	 The company should assess transactions with connected persons in advance of A1 filing. The company may apply for a waiver from the shareholder approval/announcement requirements for specified continuing connected transactions (<i>e.g.</i>, ongoing contractual relations), subject to certain conditions including: (a) the agreement term must not exceed three years; (b) the agreement must be on normal commercial terms or better, and must be fair and reasonable and in the interests of the company's shareholders as a whole; and (c) the agreement must observe the annual monetary caps on the transaction amounts. Sponsors will need to undertake diligence on the transactions subject to the waivers (including the proposed caps) to give an opinion in the prospectus that the transactions are fair and reasonable.

lssue/Task	HKEx Requirement	Comment/Timing
14 Appoint Various Intermediaries	 The company must appoint certain individuals/ intermediaries to comply with the Listing Rules requirements, including: company secretary, share registrar, compliance advisor, property valuer (if the company holds significant real property assets), among other roles. 	 The company must appoint these parties prior to A1 filing.
	 An industry consultant is typically appointed to provide industry data for the prospectus, but is not mandatory. 	
	 Sponsors will usually require the appointment of an internal control consultant to meet HKEx/SFC diligence requirements in this specialised area. 	
15 Appoint Independent Nonexecutive Directors (INEDs)	 INEDs need to represent not less than one-third of the board, subject to a minimum of three INEDs. One INED must have "appropriate professional qualifications or accounting or related financial management expertise". 	 The company must identify INED candidates prior to A1 filing. The company should reevaluate INED candidates against the HKEx independence requirements and seek additional candidates if necessary. Gender diversity is a key focus of the HKEx, and companies must in practice have at least one female board member.
16 Establish Board Committees	 HKEx requires listed companies to have an audit committee, remuneration committee and nomination committee. 	 The company must identify committee members prior to A1 filing and disclose them in the draft prospectus.
	 The audit committee must consist of only nonexecutive directors, with a majority INEDs (at least one of whom is an INED with accounting or related financial management expertise), and be chaired by an INED. 	
	 The remuneration committee must consist of a majority INEDs and be chaired by an INED. 	
	 HKEx is proposing to amend its rules to require all listed companies to have a nomination committee, consisting of a majority INEDs and chaired by an INED. 	
17 Check Articles of Association Compliance	 Company/Cayman counsel will need to prepare new HKEx-compliant post-IPO articles of association. 	 Counsel needs to incorporate certain provisions into the articles to comply with the HKEx/SFC requirements (<i>e.g.</i>, 10% or less as the threshold for minority shareholders to convene a general meeting).

lssue/Task	HKEx Requirement	Comment/Timing
18 File Disclosure of Interests in Securities	 Shareholders holding an interest of 5% or more in any class of shares (including derivative interests), and any subsequent changes in such interests crossing a whole percentage threshold, must make a "disclosure of interests" filing with the company and the SFC. Directors of the company must disclose any and all interests they, their immediate family and entities controlled by them hold in the company, and any changes in those interests. 	 The company must disclose in the prospectus such interests as at the time of listing. Post listing, the company must disclose within three business days of acquiring an interest or of any change of interest on a form prescribed by the SFC and submit online. Such forms are a matter of public record and can be viewed by members of the public online.
19 Check Option Schemes Compliance	 The company must grant all pre-IPO options before finalizing the prospectus for the IPO. Any post-IPO option schemes will need to comply with the requirements in Chapter 17 of the Listing Rules. The Listing Rules require detailed disclosures of options granted to directors and senior management; a waiver from disclosure regarding ordinary employees may be available (such that the company can disclose their option details in aggregate and not on an individual basis). 	 Restricted stock units are not strictly covered by the Listing Rules but the HKEx will nevertheless examine the terms and scope of such schemes during the vetting process.
20 Register Trademark	 The company must register the logos appearing on the prospectus cover as trademarks in Hong Kong (or have submitted the application for registration). 	 Prior to A1 submission, in addition to registering (or applying to register) its logo in Hong Kong, the company will need to engage an intellectual property law firm to provide a legal opinion that the trademark is registered in Hong Kong and submit this mandatory opinion to the HKEx as part of A1 submission.
21 Register as Non-Hong Kong Company	 The company is required to be registered as a non-Hong Kong entity under Part 16 of the Companies Ordinance. 	 The company secretary must make this filing prior to A1 submission.
22 Prepare HK Prospectus	 The company needs to create a version of the prospectus that complies with Hong Kong format/style and with the requirements in all the Listing Rules and various guidance letters issued by the HKEx. The company must prepare a Chinese language translation of the prospectus to submit at the time of A1 filing. 	 The Listing Rules and various guidance letters issued by the HKEx dictate the contents of the HK prospectus, and the level of disclosures and details are significantly more comprehensive than the typical prospectus requirements in many other jurisdictions.

lssue/Task	HKEx Requirement	Comment/Timing
23 Prepare A1 Documents and A1 Redacted Proof Prospectus	 A1 filing documents are voluminous and require coordination from all professional parties. A redacted A1 proof prospectus will be published on the HKEx's website after A1 filing. 	 The company should allow time and coordinate with printers to prepare translations of and make available the redacted A1 proof prospectus in both English and Chinese.
24 Consider Weighted Voting Rights (WVR)/Dual Class Shares	 WVR structure is permissible only if its complies with Chapter 8A of the Listing Rules. 	 Many companies will need to unwind or amend existing WVR structures.
25 Considerations for Biotech Companies	 Chapter 18A of the Listing Rules applies to all pre-revenue biotech companies. 	 Companies must have at least one "core product," among other requirements.

Contacts



Paloma Wang Partner / Hong Kong 852.3740.6888 paloma.wang@skadden.com



Kai Sun Counsel / Hong Kong 852.3740.6820 kai.sun@skadden.com



Anthony Pang Counsel / Hong Kong 852.3740.4831 anthony.pang@skadden.com



Martina To Asia Pacific Counsel / Hong Kong 852.3740.4776 martina.to@skadden.com

Timeline / Hong Kong Listing

